Folotyn for Non-Hodgkin's Lymphoma Annapolis MD

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Peter Robert Graze, MD
(410) 573-5300
900 Bestgate Rd Ste 300
Annapolis, MD
Specialties
Oncology (Cancer), Hematology-Internal Medicine
Gender
Male
Education
Medical School: Harvard Med Sch, Boston Ma 02115
Graduation Year: 1971
Hospital
Hospital: Anne Arundel Med Ctr, Annapolis, Md
Group Practice: Annapolis Medical Specialist

Data Provided by:
Robert Dallas Peterson, MD
(517) 548-1246
600 Ridgely Ave
Annapolis, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Jefferson Med Coll-Thos Jefferson Univ, Philadelphia Pa 19107
Graduation Year: 1976

Data Provided by:
Jeanine Lori Werner, MD
(410) 573-5300
900 Bestgate Rd Ste 300
Annapolis, MD
Specialties
Oncology (Cancer)
Gender
Female
Languages
Spanish
Education
Medical School: Columbia Univ Coll Of Physicians And Surgeons, New York Ny 10032
Graduation Year: 1992
Hospital
Hospital: Anne Arundel Med Ctr, Annapolis, Md
Group Practice: Annapolis Medical Specialist

Data Provided by:
Sara Lanell Horton, MD
(410) 897-0083
888 Bestgate Rd Ste 211
Annapolis, MD
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Wright State Univ Sch Of Med, Dayton Oh 45401
Graduation Year: 1992

Data Provided by:
Elizabeth Robbins, MD
2001 Medical Pkwy
Annapolis, MD
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Univ Of Ca, Davis, Sch Of Med, Davis Ca 95616
Graduation Year: 1978

Data Provided by:
Dr.Jason Taksey
(410) 573-5300
2003 Medical Pkwy #210
Annapolis, MD
Gender
M
Speciality
Oncologist
General Information
Accepting New Patients: Yes
RateMD Rating
5.0, out of 5 based on 1, reviews.

Data Provided by:
Peter R Graze
(410) 573-5300
900 Bestgate Rd
Annapolis, MD
Specialty
Hematology / Oncology, Medical Oncology

Data Provided by:
Kevin Brian Knopf, MD
(410) 573-5300
900 Bestgate Rd Ste 300
Annapolis, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Ca, San Francisco, Sch Of Med, San Francisco Ca 94143
Graduation Year: 1992

Data Provided by:
Kevin B Knopf
(410) 573-5300
900 Bestgate Rd
Annapolis, MD
Specialty
Hematology / Oncology

Data Provided by:
Curtis Harris Jr, MD
(410) 897-0083
888 Bestgate Rd Ste 211
Annapolis, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Howard Univ Coll Of Med, Washington Dc 20059
Graduation Year: 1975

Data Provided by:
Data Provided by:

Folotyn for Non-Hodgkin's Lymphoma

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com